These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32504862)

  • 21. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
    Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.
    Isobe M; Konuma T; Masuko M; Uchida N; Miyakoshi S; Sugio Y; Yoshida S; Tanaka M; Matsuhashi Y; Hattori N; Onizuka M; Aotsuka N; Kouzai Y; Wake A; Kimura T; Ichinohe T; Atsuta Y; Yanada M;
    Ann Hematol; 2021 Jul; 100(7):1849-1861. PubMed ID: 33624134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT.
    Paviglianiti A; Labopin M; Blaise D; Socié G; Bulabois CE; Lioure B; Ceballos P; Blau IW; Guillerm G; Maertens J; Chevallier P; Huynh A; Turlure P; Deconinck E; Forcade E; Nagler A; Mohty M
    Bone Marrow Transplant; 2021 May; 56(5):1077-1085. PubMed ID: 33249424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Efficacy and Safety of Mizoribine versus Mycophenolate Mofetil for the Treatment of Renal Transplantation: A Systematic Review and Meta-Analysis.
    Chen J; Liu H; Yin W; Xu Z; Chen Z; Yiu W
    Comput Intell Neurosci; 2022; 2022():5717068. PubMed ID: 35909831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
    Radujkovic A; Hegenbart U; Müller-Tidow C; Herfarth K; Dreger P; Luft T
    Ann Hematol; 2020 Apr; 99(4):855-866. PubMed ID: 32036420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
    Hamilton BK; Liu Y; Hemmer MT; Majhail N; Ringden O; Kim D; Costa L; Stuart R; Alousi A; Pidala JA; Couriel DR; Aljurf M; Antin JH; Bredeson C; Cahn JY; Cairo M; Choi SW; Dandoy C; Gale RP; Gergis U; Hematti P; Inamoto Y; Kamble RT; MacMillan M; Marks DI; Nemecek E; Nishihori T; Saad A; Savani BN; Schriber J; Seo S; Socié G; Teshima T; Verdonck LF; Waller EK; Wirk M; Spellman SR; Arora M; Chhabra S
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1744-1755. PubMed ID: 31158502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.
    Yerushalmi R; Shem-Tov N; Danylesko I; Shouval R; Nagler A; Shimoni A
    Am J Hematol; 2017 Mar; 92(3):259-268. PubMed ID: 28052467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation.
    Harada K; Fuji S; Seo S; Uchida N; Kawakita T; Yano S; Ozawa Y; Yoshioka S; Onishi Y; Noguchi Y; Onizuka M; Matsuhashi Y; Kimura T; Ichinohe T; Atsuta Y; ; ; Terakura S; Nakasone H
    Bone Marrow Transplant; 2021 Feb; 56(2):400-410. PubMed ID: 32820226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of Cytomegalovirus Infection with Post-Transplantation Cyclophosphamide in Haploidentical and HLA-Matched Unrelated Donor Transplantation.
    Jamy O; Hebert C; Dunn-Valadez S; Magnusson T; Watts N; McGwin G; Saad A
    Transplant Cell Ther; 2022 Apr; 28(4):213.e1-213.e6. PubMed ID: 35074557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
    Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
    Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of EB virus infection between short term and long term use of mycophenolate mofetil for prophylaxis of graft versus host disease after haploidentical hematopoietic stem cell transplantation].
    Yu CZ; Huang XJ; Xu LP; Liu KY; Zhang XH; Sun YQ; Liu JY; Zhao XY; Wang Y
    Zhonghua Nei Ke Za Zhi; 2021 Sep; 60(9):806-811. PubMed ID: 34445816
    [No Abstract]   [Full Text] [Related]  

  • 33. [Impact of mycophenolate mofetil prophylaxis duration on acute graft-versus-host disease after haploidentical stem cell transplantation].
    Sun YQ; Huang XJ; Xu LP; Zhang XH; Yan CH; Liu KY; Wang Y
    Zhonghua Xue Ye Xue Za Zhi; 2018 Apr; 39(4):286-291. PubMed ID: 29779322
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and Safety of a Quadruple Regimen Compared with Triple Regimens in Patients with Mycophenolic Acid-Related Gastrointestinal Complications After Renal Transplantation: A Short-Term Single-Center Study.
    Peng Z; Xian W; Sun H; Li E; Geng L; Tian J
    Ann Transplant; 2020 Feb; 25():e919875. PubMed ID: 32107364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings.
    Vogelsang GB; Arai S
    Bone Marrow Transplant; 2001 Jun; 27(12):1255-62. PubMed ID: 11548843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.
    Baron F; Sandmaier BM; Storer BE; Maris MB; Langston AA; Lange T; Petersdorf E; Bethge W; Maziarz RT; McSweeney PA; Pulsipher MA; Wade JC; Chauncey TR; Shizuru JA; Sorror ML; Woolfrey AE; Maloney DG; Storb R
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1041-8. PubMed ID: 17697966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation.
    Ueda Oshima M; Xie H; Zamora D; Flowers ME; Hill GR; Mielcarek MB; Sandmaier BM; Gooley TA; Boeckh MJ
    Blood Adv; 2023 Apr; 7(8):1394-1403. PubMed ID: 36595478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.